SIZE
96 wells/kit
INTRODUCTION
FGF-23 is a 32-kDa protein that is secreted mainly by osteocytes in bone. It has been identified that has a physiological role in regulating mineral homeostasis. FGF-23 exerts its biological functions by binding to its cognate fibroblastic growth factor receptor (FGFR) in the presence of its coreceptor Klotho. FGF-23 is produced and secreted in response to hyperphosphatemia and increased 1,25 dihydroxyvitamin D3 levels. FGF-23 concentrations increase progressively as glomerular filtration rate (GFR) declines and the level can be 1000-fold higher in patients with end-stage renal disease compared with healthy individual. This increase is considered as one of the earliest biochemical abnormality in chronic kidney disease. Therefore, FGF-23 concentration is a kind of standard to determine the existence of kidney failure.
PRINCIPLE OF THE ASSAY
This assay is a rapid quantitative sandwich ELISA. The immunoplate is pre-coated with a polyclonal antibody specific for human FGF-23. Standards or samples and a biotin labelled polyclonal antibody specific for human FGF-23 are pipetted into the wells and any human FGF-23 present is bound by the immobilized antibody. After washing away any unbound substances, streptavidin-HRP conjugate (STP-HRP) is added. After the last wash step, an HRP substrate solution is added and colour develops in proportion to the amount of human FGF-23 bound initially. The assay is stopped and the optical density of the wells determined using a microplate reader. Since the increases in absorbance are directly proportional to the amount of captured human FGF-23, the unknown sample concentration can be interpolated from a reference curve included in each assay.
SIZE
96 wells/kit
INTRODUCTION
FGF-23 is a 32-kDa protein that is secreted mainly by osteocytes in bone. It has been identified that has a physiological role in regulating mineral homeostasis. FGF-23 exerts its biological functions by binding to its cognate fibroblastic growth factor receptor (FGFR) in the presence of its coreceptor Klotho. FGF-23 is produced and secreted in response to hyperphosphatemia and increased 1,25 dihydroxyvitamin D3 levels. FGF-23 concentrations increase progressively as glomerular filtration rate (GFR) declines and the level can be 1000-fold higher in patients with end-stage renal disease compared with healthy individual. This increase is considered as one of the earliest biochemical abnormality in chronic kidney disease. Therefore, FGF-23 concentration is a kind of standard to determine the existence of kidney failure.
PRINCIPLE OF THE ASSAY
This assay is a rapid quantitative sandwich ELISA. The immunoplate is pre-coated with a polyclonal antibody specific for human FGF-23. Standards or samples and a biotin labelled polyclonal antibody specific for human FGF-23 are pipetted into the wells and any human FGF-23 present is bound by the immobilized antibody. After washing away any unbound substances, streptavidin-HRP conjugate (STP-HRP) is added. After the last wash step, an HRP substrate solution is added and colour develops in proportion to the amount of human FGF-23 bound initially. The assay is stopped and the optical density of the wells determined using a microplate reader. Since the increases in absorbance are directly proportional to the amount of captured human FGF-23, the unknown sample concentration can be interpolated from a reference curve included in each assay.
